8-K: REGEN BIOPHARMA Issues 23.68M Shares in Equity Sales

REGEN BIOPHARMA, INC. announced the issuance of 23.68 million common shares across multiple transactions in October and November 2025, raising $191,800 in cash and converting $43,740 of debt.

Summary

• REGEN BIOPHARMA, INC. issued a total of 23,680,000 common shares through several unregistered sales events between October 8, 2025, and November 10, 2025.
• The company raised $191,800 in cash through the issuance of 19,180,000 common shares under Tier 2 Regulation A Offerings.
• An additional 4,500,000 common shares were issued to satisfy $30,204 of principal convertible indebtedness and $13,536 of accrued interest, totaling $43,740 in debt conversion.
• All shares sold for cash consideration were issued at an implied price of $0.01 per share.
• The shares were sold directly through management, with no underwriters, commissions, advertisements, or general solicitations involved for the Section 4(a)(2) issuance.

Sentiment

Score: 4

Explanation: While the company successfully raised capital and reduced debt, the significant dilution at a very low per-share price ($0.01) suggests underlying challenges in valuation and capital structure, leading to a slightly negative sentiment.

Positives

• Successfully raised $191,800 in cash through equity sales.
• Converted $43,740 of convertible indebtedness (principal and interest) into equity, reducing the company's debt burden.

Negatives

• Significant dilution of existing shareholders due to the issuance of 23,680,000 new common shares.
• The implied price of $0.01 per share for the cash-based equity raises indicates a very low valuation for the company's common stock.

Risks

• Further significant dilution of existing shareholders if the company continues to raise capital at similar low valuations.
• Reliance on direct sales by management for capital raises may limit the reach and efficiency of fundraising efforts compared to broader market offerings.
• The low share price could impact investor confidence and the company's ability to attract institutional investment.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future operations or financial performance, focusing solely on past equity issuance events.

Management Comments

• David Koos, Chairman and Chief Executive Officer, signed the report on behalf of REGEN BIOPHARMA, INC.

Industry Context

Biopharmaceutical companies, especially those in early development stages, frequently rely on equity financing to fund research and development, clinical trials, and operational expenses. The issuance of shares at a low price point and through direct sales by management is common for smaller companies with limited access to broader capital markets, often indicating a high-risk, early-stage profile.

Comparison to Industry Standards

• Issuing shares at $0.01 per share is significantly below typical valuations for established public companies and suggests a very early-stage or distressed valuation, even within the often speculative biopharma sector.
• Direct sales by management, without underwriters, are not uncommon for micro-cap companies or specific private placement-like offerings (such as Section 4(a)(2) or smaller Regulation A tiers), but can limit the reach and efficiency of capital raising compared to larger, underwritten public offerings.
• The conversion of convertible debt into equity is a standard mechanism for managing liabilities, particularly for companies that may face cash flow constraints.

Stakeholder Impact

• Existing shareholders face significant dilution of their ownership percentage due to the issuance of 23.68 million new common shares.
• Creditors holding the convertible indebtedness benefited from the conversion of their debt into equity, resolving a liability for the company.

Key Dates

Recommendation

The filing reports past capital-raising activities that involved substantial dilution at a very low share price. While the company secured funding and reduced debt, the terms of these raises are concerning for existing shareholders. Without further operational updates or strategic shifts, the current information suggests a 'hold' position for existing investors, acknowledging the capital infusion but also the significant dilution and low valuation. A 'sell' might be considered if the dilution trend continues without corresponding value creation.

Keywords

REGEN BIOPHARMA, equity issuance, common shares, Regulation A Offering, debt conversion, dilution, capital raise, 8-K filing, unregistered sales